Multiple Myeloma

New Reference: Daratumumab with Lenalidomide and Bortezomib in 1st Line Multiple Myeloma

2023-11-20

  • Study



  • Efficacy



  • Safety




    • Lancet Haematol 2023 Oct;10(10):e825-e837

    Voorhees PM Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial

    http://doi.org/10.1016/S2352-3026(23)00217-X

    Reviewed by Ulas D. Bayraktar, MD on Nov 20, 2023